Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug

CNBC’s Angelica Peebles joins ‘Fast Money’ to report on Bristol Myers Squibb’s stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.